Pipeline Table

RNS Number : 4404Z

AstraZeneca PLC

06 February 2014

 



Development Pipeline as at

31 December 2013

Line Extensions

Compound	Mechanism	Area Under Investigation	Date Commenced Phase	Estimated Filing
				US	EU	Japan	China
Cardiovascular
Brilinta/ Brilique EUCLID	ADP receptor antagonist	outcomes study in patients with PAD	4Q 2012	2016	2016	2016	2017
Brilinta / Brilique PEGASUS-TIMI 54	ADP receptor antagonist	outcomes study in patients with prior MI	4Q 2010	2015	2015	2015	2017
Brilinta/ Brilique SOCRATES1	ADP receptor antagonist	outcomes study in patients with stroke or TIA	1Q 2014	2016	2016	2016	2017
Brilinta/ Brilique THEMIS	ADP receptor antagonist	outcomes study in patients with Type 2 diabetes and CAD but without previous history of MI or stroke		2017	2017	2018	2018
Bydureon Dual Chamber Pen	GLP-1 receptor agonist	diabetes		Filed	Filed	2Q 2014
Bydureon EXSCEL	GLP-1 receptor agonist	outcomes study	2Q 2010	2018	2018	2018
Bydureon weekly suspension	GLP-1 receptor agonist	diabetes	1Q 2013	2015	2015
Farxiga/Forxiga2 DECLARE	SGLT2 inhibitor	outcomes study	2Q 2013	2020	2020
Kombiglyze XR/ Komboglyze FDC3	DPP-4 inhibitor/ metformin FDC	diabetes		Launched	Launched		Filed
Onglyza SAVOR-TIMI 53	DPP-4 inhibitor	outcomes study	2Q 2010	1Q 2014	1Q 2014		2015
saxagliptin/ dapagliflozin FDC	DPP-4 inhibitor/SGLT2 inhibitor FDC	diabetes	2Q 2012	2015	2015
Xigduo	SGLT2 inhibitor/ metformin FDC	diabetes		Filed	Approved4

Compound	Mechanism	Area Under Investigation	Date Commenced Phase	Estimated Filing
				US	EU		Japan	China
Gastrointestinal
Entocort	glucocorticoid steroid	Crohn's disease/ulcerative colitis		Launched	Launched		2015	N/A
Linaclotide#	GC-C receptor peptide agonist	irritable bowel syndrome with constipation (IBS-C)		N/A	N/A		N/A	2015
Nexium	proton pump inhibitor	peptic ulcer bleeding		Filed5	Launched		N/A	Launched
Neuroscience
Diprivan#	sedative and anaesthetic	conscious sedation			Launched		2H 2014	Launched
Oncology
Caprelsa	VEGFR/ EGFR tyrosine kinase inhibitor with RET kinase activity	differentiated thyroid cancer	2Q 2013	2016	2016	2016
Faslodex	oestrogen receptor antagonist	1st line advanced breast cancer	4Q 2012	2016	2016	2016		2016
Iressa	EGFR tyrosine kinase inhibitor	treatment beyond progression	1Q 2012		2015	2015		2015
Respiratory, Inflammation & Autoimmunity
Symbicort6	inhaled steroid/ long-acting β2 agonist	Breath Actuated Inhaler asthma / COPD	4Q 2011

^# Partnered product

¹ First subject dosed in January 2014 for SOCRATES

²  Farxiga US; Forxiga rest of world

³ Kombiglyze XR US; Komboglyze FDC EU

⁴ Approved January 2014

⁵ 2^nd CRL received from FDA in 2011. AZ response submitted to FDA in December 2012 and application remains under FDA review

⁶ Filing delayed pending evaluation of alternative device design

NMEs

Phase III/Registration

Compound

Mechanism

Area Under Investigation

Date Commenced Phase

Estimated Filing

US

EU

Japan

China

Cardiovascular

Brilinta /Brilique

ADP receptor antagonist

arterial thrombosis

Launched

Launched

Filed

Launched

Epanova#

omega-3 free fatty acids

hypertri-glyceridaemia

Filed

Farxiga/ Forxiga1

SGLT2 inhibitor

diabetes

Approved2

Launched

Filed

Filed

metreleptin

leptin analogue

lipodystrophy

Filed

2015

N/A

Infection

CAZ AVI (CAZ104)#

cephalosporin/beta lactamase inhibitor

serious infections

1Q 2012

N/A

4Q 2014

2015

2016

CAZ AVI (CAZ104)#

cephalosporin/beta lactamase inhibitor

hospital-acquired pneumonia/ventilator-associated pneumonia

2Q 2013

N/A

2017

2017

Zinforo (ceftaroline)#

extended spectrum cephalosporin with affinity to penicillin- binding proteins

pneumonia / skin infections

N/A

Launched

N/A

1H 2014

Neuroscience

naloxegol (NKTR-118)#

oral peripherally-acting mu-opioid receptor antagonist

opioid-induced constipation

Filed

Filed

Oncology

Caprelsa

VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity

medullary thyroid cancer

Launched

Launched

3Q 2014

Filed

moxetumomab pasudotox#

anti-CD22 recombinant immunotoxin

hairy cell leukaemia

2Q 2013

2018

2018

olaparib

PARP inhibitor

gBRCAm PSR ovarian cancer

1Q 2014

Filed

olaparib SOLO-1

PARP inhibitor

1st line gBRCAm ovarian cancer

3Q 2013

2017

2017

2017

2017

olaparib SOLO-2

PARP inhibitor

gBRCAm PSR ovarian cancer

3Q 2013

2016

2016

2016

2016

olaparib GOLD

PARP inhibitor

2nd line gastric cancer

3Q 2013

2017

2018

selumetinib (AZD6244) (ARRY-142886)#

MEK inhibitor

2nd line KRAS+ NSCLC

4Q 2013

2017

2017

Respiratory, Inflammation & Autoimmunity

benralizumab#

anti-IL-5R MAb

severe asthma

4Q 2013

2016

2016

brodalumab#

anti-IL-17R MAb

psoriasis

3Q 2012

2015

2015

lesinurad

selective inhibitor of URAT1

chronic management of hyperuricaemia in patients with gout

4Q 2011

2H 2014

2H 2014

2017

PT003 GFF

LABA/LAMA

COPD

2Q 2013

2015

2016

^#Partnered product

¹Farxiga US; Forxiga rest of world 

²Approved January 2014

NMEs

Phases I and II

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing
					US	EU	Japan	China
Cardiovascular
AZD1722#	NHE3 inhibitor	ESRD-Pi / CKD- with T2DM/ ESRD-Fluid Retention	II	1Q 2013
AZD4901	NK3	polycystic ovarian syndrome	II	2Q 2013
roxadustat (FG-4592)#	hypoxia-inducible factor inhibitor	anaemia in CKD/end-stage renal disease	II1		2018	N/A	N/A	2016
MEDI6012	LCAT	ACS	I	1Q 2012
Infection
AZD5847	oxazolidinone anti-bacterial inhibitor	tuberculosis	II	4Q 2012
CXL#	beta lactamase inhibitor/ cephalosporin	MRSA	II	4Q 2010
ATM AVI	BL/BLI	targeted serious bacterial infections	I	4Q 2012
AZD0914	GyrAR	serious bacterial infections	I	4Q 2013
MEDI-550	pandemic influenza virus vaccine	pandemic influenza prophylaxis	I	2Q 2006
MEDI-559 (PRVV)	paediatric RSV vaccine	RSV prophylaxis	I	4Q 2008
MEDI4893	staph alpha toxin YTE MAb	hospital-acquired pneumonia / serious S. aureus infection	I	1Q 2013
MEDI92872	H7N9 vaccine	avian influenza	I	4Q 2013
Neuroscience
AZD3241	myeloper-oxidase (MPO) inhibitor	Parkinson's disease	II	2Q 2012
AZD5213	histamine-3 receptor  antagonist	Tourette's syndrome/ neuropathic pain	II	4Q 2013
AZD3293#	beta secretase	Alzheimer's disease	I	4Q 2012
AZD6423	NMDA	suicidal ideation	I	3Q 2013

^#Partnered product

¹In-licensed asset in late-development but the Phase III AstraZeneca programme has yet to randomise its first patient

²Vaccine in development through a CRADA with NIAID

NMEs

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing
					US	EU	Japan	China
Oncology
AZD1775#	Wee-1 inhibitor	ovarian cancer	II	4Q 2012
AZD2014	TOR kinase inhibitor	solid tumours	II	1Q 2013
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	II	4Q 2011
MEDI-551#	anti-CD19 MAb	haematological malignancies	II	1Q 2012
MEDI-573#	anti-IGF MAb	MBC	II	4Q 2011
olaparib	PARP inhibitor	breast cancer	II	1Q 2012
selumetinib (AZD6244) (ARRY-142886)#	MEK inhibitor	various cancers	II	4Q 2008
tremelimumab	anti-CTLA4 MAb	mesothelioma	II	2Q 2013
AZD1208	PIM kinase inhibitor	haematological malignancies	I	1Q 2012
AZD5363#	AKT inhibitor	solid tumours	I	4Q 2010
AZD6738	ATR	CLL/ head & neck	I	4Q 2013
AZD8186	PI3 kinase beta inhibitor	solid tumours	I	2Q 2013
AZD9150#	STAT3 inhibitor	haematological malignancies	I	1Q 2012
AZD9291	epidermal growth factor inhibitor	solid tumours	I	1Q 2013
MEDI-565#	anti-CEA BiTE	solid tumours	I	1Q 2011
MEDI0639#	anti-DLL-4 MAb	solid tumours	I	2Q 2012
MEDI0680 (AMP-514)	anti-PD-1MAb	solid tumours	I	4Q 2013
MEDI3617#	anti-ANG-2 MAb	solid tumours	I	4Q 2010
MEDI4736#	anti-PD-L1 MAb	solid tumours	I	3Q 2012
MEDI4736# + tremelimumab	anti-PD-L1 MAb + anti-CTLA4 MAb	solid tumours	I	4Q 2013
MEDI4736# + dabrafenib + trametinib3	anti-PD-L1 MAb + BRAF inhibitor + MEK inhibitor	melanoma	I	1Q 2014
MEDI6469#	murine anti-OX40 MAb	solid tumours	I	1Q 2006
moxetumomab pasudotox#	anti-CD22 recombinant immunotoxin	pALL	I	3Q 2008
volitinib# (AZD6094)	MET inhibitor	solid tumours	I	1Q 2012

^#Partnered product

³MedImmune-sponsored study in collaboration with GlaxoSmithKline. First patient dosed in January 2014

NMEs

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing
					US	EU	Japan	China
Respiratory,  Inflammation & Autoimmunity
AZD2115#	MABA	COPD	II	2Q 2012
AZD5069	CXCR2	asthma	II	4Q 2010
benralizumab#	anti-IL-5R MAb	COPD	II	4Q 2010
brodalumab#	anti-IL-17R MAb	asthma / psoriatic arthritis	II	2Q 2013
mavrilimumab#	anti-GM-CSFR MAb	rheumatoid arthritis	II	1Q 2010
MEDI-546#	anti-IFN-alphaR MAb	SLE	II	1Q 2012
MEDI2070#	anti-IL-23 MAb	Crohn's disease	II	1Q 2013
MEDI7183#	anti-a4b7 MAb	Crohn's disease / ulcerative colitis	II	4Q 2012
MEDI8968#	anti-IL-1R MAb	COPD, HS	II	4Q 2011
RDEA3170	selective inhibitor of URAT1	chronic management of hyperuricaemia in patients with gout	II	3Q 2013
sifalimumab#	anti-IFN-alpha MAb	SLE	II	3Q 2008
tralokinumab	anti-IL-13 MAb	asthma / IPF	II	1Q 2008
AZD1419	TLR9	asthma	I	3Q 2013
AZD4721	CXCR2	COPD	I	3Q 2013
AZD7624	ip38i	COPD	I	1Q 2013
AZD8848#	inhaled TLR7	asthma	I	2Q 2012
MEDI-551#	anti-CD19 MAb	multiple sclerosis	I	3Q 2012
MEDI5872#	anti-B7RP1 MAb	SLE	I	4Q 2008
MEDI9929#	anti-TSLP MAb	asthma	I	4Q 2008
PT010	LAMA/LABA/ICS	COPD	I	4Q 2013

^#Partnered product

Development Pipeline - Discontinued Projects between 1 January 2013 and 31 December 2013

Infection

NME/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NME	MEDI-557	Safety/Efficacy	RSV prevention in high risk adults (COPD/CHF/other)

Neuroscience

NME/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NME	AZD1446	Safety/Efficacy	Alzheimer's disease
NME	AZD3480#	Safety/Efficacy	Alzheimer's disease
NME	AZD5213	Hypothesis risk	Alzheimer's disease
NME	AZD6765	Safety/Efficacy	major depressive disorder
NME	MEDI5117	Safety/Efficacy	OA pain

Oncology

NME/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NME	AZD8330#(ARRY 424704)	Safety/Efficacy	solid tumours
NME	fostamatinib#	Safety/Efficacy	haematological malignancies
NME	MEDI-575#	Safety/Efficacy	NSCLC

Respiratory, Inflammation & Autoimmunity

NME/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NME	AZD5423#	Safety/Efficacy	COPD
NME	AZD7594#	Safety/Efficacy	COPD
NME	fostamatinib#	Safety/Efficacy	rheumatoid arthritis
NME	MEDI4212	Safety/Efficacy	asthma
NME	MEDI7814	Economic	COPD
LCM	tralokinumab	Safety/Efficacy	UC

^#Partnered product

Completed Projects

Compound	Mechanism	Area Under Investigation	Launch Status
			US	EU	Japan	China
Cardiovascular
Forxiga (dapagliflozin)	SGLT2 inhibitor	diabetes - add on to DPP-4		Approved
Forxiga (dapagliflozin)	SGLT2 inhibitor	diabetes - add on to metformin long-term data		Approved
Forxiga (dapagliflozin)1	SGLT2 inhibitor	diabetes -  in patients with high CV risk - study 18 and 19 long-term data
Forxiga (dapagliflozin)	SGLT2 inhibitor	diabetes - triple therapy (dapa+met+ SU)		Approved
Infection
Q-LAIV Flu Vaccination	live, attenuated, intranasal influenza virus vaccine  (quadrivalent)	seasonal influenza	Approved	Approved

¹Studies 18/19 complete. No filing planned from this data

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Submission dates shown for assets in Phase III and beyond.

 

END

 

 

MSCEAKAKEALLEEF